Thermo Fisher Scientific (TMO) EBITDA Margin (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported EBITDA Margin for 18 consecutive years, with 16.93% the latest figure, recorded in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 16.93%, up 37.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.46% (up 24.0% YoY), and the FY2025 annual result was 17.38%, up 27.0% from the prior year.
• EBITDA Margin was 16.93% for Q1 2026 at Thermo Fisher Scientific, down from 18.46% in the prior quarter.
• Over five years, EBITDA Margin peaked at 23.87% in Q2 2022 and troughed at 14.59% in Q2 2023.
• Average EBITDA Margin over 5 years is 17.24%, with a median of 17.03% recorded in 2023.
• Year-over-year, EBITDA Margin sank 928 bps in 2023 and soared 250 bps in 2024.
• Over 5 years, EBITDA Margin stood at 16.25% in 2022, then rose by 5 bps to 17.03% in 2023, then increased by 4 bps to 17.69% in 2024, then gained by 4 bps to 18.46% in 2025, then decreased by 8 bps to 16.93% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 16.93% in Q1 2026, 18.46% in Q4 2025, and 17.45% in Q3 2025.